TITLE

Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis

PUB. DATE
January 2009
SOURCE
Journal of Teaching in Physical Education;Jan2009, Vol. 28 Issue 1, p311
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
36133944

 

Related Articles

  • Ibandronic acid unlikely choice for IBD-related fracture prevention.  // PharmacoEconomics & Outcomes News;4/19/2008, Issue 551, p6 

    The article discusses research being done on the use of ibandronate for inflammatory bowel disease- (IBD) related fracture prevention. It references a study by S. Kreck, L. Klaus et al, published in the January 2008 issue of "PharmaEconomics." According to study researchers, too few fractures...

  • Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis. Kreck, Simon; Klaus, Jochen; Leidl, Reiner; von Tirpitz, Christian; Konnopka, Alexander; Matschinger, Herbert; König, Hans-Helmut // PharmacoEconomics;2008, Vol. 26 Issue 4, p311 

    Background: Osteoporosis is a frequent complication in patients with inflammatory bowel disease. Recent studies have shown bisphosphonates to considerably reduce fracture risk in patients with osteoporosis, and preventing fractures with bisphosphonates has been reported to be cost effective in...

  • IBANDRONATE IS COST-EFFECTIVE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS: A COMPARISION OF BISPHOSPHONATES.  // Osteoporosis International;Mar2006 Supplement 1, Vol. 17, pS11 

    The article presents the abstract of the research "Ibandronate is Cost-Effective in the Treatment of Postmenopausal Osteoporosis: A Comparison of Bisphosphonates."

  • CITATIONS AND CLINICIANS' NOTES: OSTEOARTHRITIS.  // Current Medical Literature: Rheumatology;2004, Vol. 23 Issue 2, p37 

    Presents clinicians' notes about osteoarthritis. Role of oral daily ibandronate in preventing bone loss in early postmenopausal women without osteoporosis; Role of beta-adrenergic blockers in reducing the risk of fracture; Racial differences in the effect of early milk consumption on peak and...

  • Treatment of Osteoporosis and Prevention of New Fractures: Role of Intravenously Administered Bisphosphonates.  // Endocrine Practice;Jul2009, Vol. 15 Issue 5, p483 

    Objective: To evaluate the usefulness of intravenously administered bisphosphonates for improving absorption, tolerability, adherence, and outcomes in the treatment and prevention of osteoporosis.Methods: Data published from 1996 to 2009 relevant to the treatment of osteoporosis, with emphasis...

  • Osteoporosis.  // Current Medical Literature: Rheumatology;2008, Vol. 27 Issue 3, p86 

    The article discusses research being done on a range of therapies for the treatment of osteoporosis and prevention of fracture in men and women with low bone density or osteoporosis. It references a study by C. MacLean et al which appeared in a 2008 issue of "Annals of Internal Medicine." The...

  • Ibandronate in Benign Bone Disease. Winzenberg, Tania; Jones, Graeme // Reviews on Recent Clinical Trials;May2008, Vol. 3 Issue 2, p139 

    Ibandronate is a potent bisphosphonate which has been most thoroughly assessed in benign bone disease for use in the management of postmenopausal osteoporosis. Its use in corticosteroid-induced osteoporosis, Paget's disease and uncommon benign bone conditions such as localised transient...

  • Ibandronate: A Review of its Use in the Management of Postmenopausal Osteoporosis. Frampton, James E.; Perry, Caroline M. // Drugs;2008, Vol. 68 Issue 18, p2683 

    Abstract Ibandronate (ibandronic acid; Bonviva®, Boniva®), a nitrogen-containing bisphosphonate available in once-monthly oral and quarterly intravenous formulations for intermittent administration, has been approved for the treatment of osteoporosis in postmenopausal women in the EU, the...

  • SOFT STOOLS, SOFT BONES AND SOFT EVIDENCE?—WHAT INFLAMMATORY BOWEL DISEASE PATIENT THINK OF OSTEOPOROSIS MEDICATION. Oliver, D.G.; Trewby, P.N. // Gut;Apr2003 Supplement 1, Vol. 52, pA70 

    Background: The British Society of Gastroenterology guidelines for osteoporosis in inflammatory bowel disease imply the screening of a large proportion of inflammatory bowel disease patients and treatment with antiresorptive medication if necessary. Despite this, only a small percentage of...

  • Strong bones in later life. Woolf, Anthony D. // Bulletin of the World Health Organization;1999, Vol. 77 Issue 5, p368 

    Editorial. Comments on strategies to prevent osteoporosis and fracture. Ignorance of the burden of osteoporosis-associated fractures in the elderly; Examination of data on cost-effectiveness for any intervention; Benefits for individual recipients of an intervention.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics